eli lilly and company zepbound

Lilly, Zepbound and weight loss

Lilly's next-gen drug shows greater weight loss than Zepbound in late-stage trial

Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a late-stage trial, outperforming its blockbuster drug Zepbound and reinforcing the company's lead in the fast-growing market.

· 13d · on MSN

Eli Lilly cuts Zepbound prices in competitive weight loss drug market battle

· 2d

Eli Lilly Further Cements Itself As The King Of Weight Loss

Eli Lilly: Short-Term Upside Exhausted (Rating Downgrade)

Discover why Eli Lilly's stock downturn may present new opportunities. Learn about valuation, Zepbound pricing, and 2026 ...

8don MSN

Eli Lilly's stock drops as it slashes the price of Zepbound: Time to buy the dip?

Eli Lilly's decision to reduce the price of its popular weight loss drug makes more sense than it appears at first. The ...

A better Ozempic? Eli Lilly’s new obesity drug cut weight by 23%, study finds

In an added benefit, more than one in eight people taking the highest dose of Retratrutide were completely free of arthritic ...

WHIO

Eli Lilly, Walmart partner to bring Zepbound to customers with direct-to-consumer pricing

Eli Lilly and Company and Walmart have announced a partnership to offer Zepbound single-dose vials at Walmart pharmacies. The move will start nationwide in mid-November and will have direct-to ...

3don MSN

Think Eli Lilly Is Expensive? This Metric Says Otherwise.

Eli Lilly 's (NYSE: LLY) share price has soared over the past five years (up 530%). In fact, it's hard to find a single ...

Can Eli Lilly Sustain Its Obesity Momentum as Newer Players Emerge?

LLY leans on tirzepatide and a deep late-stage pipeline to defend its obesity momentum as new rivals make rapid progress in ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results